[1]张润南,赵中华,李亚桐,等.肠道微生态改变对肝硬化的影响研究进展[J].肠外与肠内营养杂志,2025,(01):54-59.[doi:10.16151/j.1007-810x.2025.01.009]
　ZHANG Run-nan,ZHAO Zhong-hua,LI Ya-tong,et al.Research progress in the effects of alterations in intestinal microecology on liver cirrhosis[J].PARENTERAL & ENTERAL NUTRITION,2025,(01):54-59.[doi:10.16151/j.1007-810x.2025.01.009]
点击复制

肠道微生态改变对肝硬化的影响研究进展()
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2025年01期
页码:
54-59
栏目:
综述
出版日期:
2025-04-02

文章信息/Info

Title:
Research progress in the effects of alterations in intestinal microecology on liver cirrhosis
作者:
张润南1; 赵中华2; 李亚桐 2; 陈强谱1; 2
滨州医学院附属医院，1.临床营养科；2.肝胆外科，山东滨州256600
Author(s):
ZHANG Run-nan1;  ZHAO Zhong-hua2;  LI Ya-tong1;  CHEN Qiang-pu1; 2
1. Department of Clinical Nutrition；2. Department of Hepatobiliary Surgery, Affiliated Hospital of Binzhou Medical University, Binzhou 256600,Shandong, China
关键词:
肝硬化 ; 肠道微生态 ; 肠道菌群 ; 肌肉减少症
Keywords:
Liver cirrhosis;  Intestinal microecology;  Intestinal flora;  Sarcopenia
分类号:
R459.3
DOI:
10.16151/j.1007-810x.2025.01.009
文献标志码:
A
摘要:
肠道微生态改变与肝硬化及肝硬化并发肌肉减少症的关系密切，目前已经有一些治疗手段通过对肠道菌群进行干预，从而帮助治疗肝硬化及肝硬化肌少症，近年来相关研究取得了一定进展。本文从肝硬化时肠道微生态的具体变化、肠道微生态改变影响肝硬化病人肌肉状态的机制、肠道微生态干预在肝硬化及肝硬化肌少症防治中的价值几个方面进行综述，以期对肝硬化及并发的肌少症的诊治起到一定借鉴作用。
Abstract:
Intestinal microecological changes are closely related to liver cirrhosis and cirrhosis-related sarcopenia. Studies has demonstrated that interventions targeting the intestinal microbiota could contribute to the treatment of cirrhosis and cirrhosis-related sarcopenia. Here we reviewed the research progress on the alterations in intestinal microbiota during liver cirrhosis and the underlying mechanisms by which these changes impacted the development of the disease. The potential of microbiota-targeted interventions in both preventing and treating liver cirrhosis and related sarcopenia was also discussed, which might provide valuable insights into clinical diagnosis andmanagement of the disease.

参考文献/References:


[1] Sebastián Domingo JJ, Sánchez Sánchez C. From the intestinal flora to the microbiome[J]. Rev Esp Enferm Dig, 2018, 110(1):51-56.
[2] Grenham S, Clarke G, Cryan JF, et al. Brain-gut-microbe communication in health and disease[J]. Front Physiol, 2011,2: 94.
[3] Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome[J]. Nature, 2011, 473(7346): 174-180.
[4] Cariou B, Staels B. The expanding role of the bile acid receptor FXR in the small intestine[J]. J Hepatol, 2006, 44(6): 1213-1215.
[5] Bajaj JS, Betrapally NS, Gillevet PM. Decompensated cirrhosis and microbiome interpretation[J]. Nature, 2015, 525(7569):E1-E2.
[6] 梁灿灿, 庞 澜, 柯 月, 等. 非酒精性脂肪性肝病病人肠道微生态系统变化及其对机体炎症反应的影响机制[J]. 肠外与肠内营养, 2020, 27(6): 335-339.
[7] Lee PC, Lee KC, Yang TC, et al. Sarcopenia-related gut microbial changes are associated with the risk of complications in people with cirrhosis[J]. JHEP Rep, 2022, 5(1): 100619.
[8] Ren XJ, Hao SS, Yang CL, et al. Alterations of intestinal microbiota in liver cirrhosis with muscle wasting[J]. Nutrition,2021, 83: 111081.
[9] Ponziani FR, Picca A, Marzetti E, et al. Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia[J].Liver Int, 2021, 41(6): 1320-1334.
[10] Fukui H, Wiest R. Changes of intestinal functions in liver cirrhosis[J]. Inflamm Intest Dis, 2016, 1(1): 24-40.
[11] Zeng YB, Chen SJ, Fu Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27(2): 143-155.
[12] Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol,2021, 75Suppl 1(Suppl 1): S67-S81.
[13] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577.
[14] 范圣先, 李幼生. 肠道细菌移居: 短肠综合征肠道微生态紊乱的核心[J]. 中华消化外科杂志, 2015, 14(12): 1059-1062.
[15] 徐兴伟, 范朝刚, 李秋荣. 肠道菌群对免疫功能的影响和疾病研究的新进展[J]. 肠外与肠内营养, 2017, 24(2): 118-121.
[16] Cinar MU, Islam MA, Pr?ll M, et al. Evaluation of suitable reference genes for gene expression studies in porcine PBMCs in response to LPS and LTA[J]. BMC Res Notes, 2013, 6: 56.
[17] Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302(1): G168-G175.
[18] Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders[J]. Gastroenterology, 2020, 159(3): 849-863.
[19] Goel GA, Deshpande A, Lopez R, et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression[J]. Clin Gastroenterol Hepatol, 2012, 10(4): 422-427.
[20] Metges CC. Contribution of microbial amino acids to amino acid homeostasis of the host[J]. J Nutr, 2000, 130(7): 1857S-1864S.
[21] Bach Knudsen KE, L?rke HN, Hedemann MS, et al. Impact of diet-modulated butyrate production on intestinal barrier function and inflammation[J]. Nutrients, 2018, 10(10): 1499.
[22] Pohl K, Moodley P, Dhanda A. The effect of increasing intestinal short-chain fatty acid concentration on gut permeability and liver injury in the context of liver disease: a systematic review[J]. J Gastroenterol Hepatol, 2022, 37(8): 1498-1506.
[23] 张佩彦, 秦肖含, 王玉珍. 肌少症与肝硬化的研究进展[J]. 肠外与肠内营养, 2022, 29(1): 57-61, 64.
[24] 徐 骁, 陈 昊, 鲁 迪, 等. 肌肉减少症: 肝移植的新挑战[J].中华消化外科杂志, 2021, 20(10): 1025-1030.
[25] Nikkhah A, Ejtahed HS, Ettehad Marvasti F, et al. The critical role of gut microbiota dysbiosis in skeletal muscle wasting: a systematic review[J]. J Appl Microbiol, 2023, 134(1): lxac014.
[26] Belzer C, Chia LW, Aalvink S, et al. Microbial metabolic networks at the mucus layer lead to diet-independent butyrate and vitamin B12 production by intestinal symbionts[J]. mBio, 2017, 8(5): e00770-17.
[27] Liu CR, Cheung WH, Li J, et al. Understanding the gut microbiota and sarcopenia: a systematic review[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1393-1407.
[28] Han JW, Kim DI, Nam HC, et al. Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis[J]. Clin Mol Hepatol, 2022, 28(2): 219-231.
[29] 刘晏东, 邓 强, 彭冉东, 等. 基于肠道微生态探析肌骨衰减疾病的研究概况[J]. 肠外与肠内营养, 2023, 30(5): 309-314.
[30] Behrouzi P, Grootswagers P, Keizer PLC, et al. Dietary intakes of vegetable protein, folate, and vitamins B-6 and B-12 are partially correlated with physical functioning of Dutch older adults using copula graphical models[J]. J Nutr, 2020, 150(3): 634-643.
[31] Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V, et al. Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes[J]. Front Genet, 2015,6: 148.
[32] Merli M, Iebba V, Giusto M. What is new about diet in hepatic encephalopathy[J]. Metab Brain Dis, 2016, 31(6): 1289-1294.
[33] Allen JM, Mailing LJ, Niemiro GM, et al. Exercise alters gut microbiota composition and function in lean and obese humans[J]. Med Sci Sports Exerc, 2018, 50(4): 747-757.
[34] Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial[J]. Gastroenterology, 2014, 147(6): 1327-1337.e3.
[35] Cao Q, Yu CB, Yang SG, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: a metaanalysis[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(1): 9-16.
[36] Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(8): 491-502.
[37] Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis[J]. Cochrane Database Syst Rev, 2016, 2016(5): CD003044.
[38] Hong AS, Tun KM, Hong JM, et al. Fecal microbiota transplantation in decompensated cirrhosis: a systematic review on safety and efficacy[J]. Antibiotics (Basel), 2022, 11(7): 838.
[39] Liu ZJ, Zhu SW, He MB, et al. Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity[J]. Chin Med J (Engl), 2022, 135(14): 1716-1727.
[40] Ponziani FR, Scaldaferri F, De Siena M, et al. Increased faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment[J]. Benef Microbes, 2020, 11(6): 519-525.
[41] Kawaratani H, Kondo Y, Tatsumi R, et al. Long-term efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: a multicenter retrospective study[J]. J Clin Med,2022, 11(6): 1571.
[42] 苏玲玲, 黎小银, 易宏波, 等. 原花青素通过塑造肠道菌群调节免疫应答的作用与机制研究进展[J]. 动物营养学报, 2023, 35(3): 1454-1467.
[43] Wu ZH, Huang SM, Li TT, et al. Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis[J]. Microbiome, 2021, 9(1): 184.
[44] Prokopidis K, Giannos P, Kirwan R, et al. Impact of probiotics on muscle mass, muscle strength and lean mass: a systematic review and meta-analysis of randomized controlled trials[J]. J Cachexia Sarcopenia Muscle, 2023, 14(1): 30-44.
[45] Byeon HR, Jang SY, Lee Y, et al. New strains of akkermansia muciniphila and faecalibacterium prausnitzii are effective for improving the muscle strength of mice with ImmobilizationInduced muscular atrophy[J]. J Med Food, 2022, 25(6): 565-575.
[46] Theou O, Jayanama K, Fernández-Garrido J, et al. Can a prebiotic formulation reduce frailty levels in older people?[J]. J Frailty Aging, 2019, 8(1): 48-52.
[47] Buigues C, Fernández-Garrido J, Pruimboom L, et al. Effect of a prebiotic formulation on frailty syndrome: a randomized, doubleblind clinical trial[J]. Int J Mol Sci, 2016, 17(6): 932.
[48] Manzhalii E, Moyseyenko V, Kondratiuk V, et al. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment[J]. World J Hepatol, 2022, 14(3): 634-646.
[49] Chen HT, Xu C, Zhang F, et al. The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats[J]. Cancer Chemother Pharmacol, 2020, 85(6): 1049-1062.

相似文献/References:

[1]房 良,荆 雪,田字彬.肌肉减少症与肝硬化的临床研究进展[J].肠外与肠内营养杂志,2018,(05):308.[doi:10.16151/j.1007-810x.2018.05.013]
　FANG Liang,JING Xue,TIAN Zi-bin.A review of the relationship between sarcopenia and cirrhosis[J].PARENTERAL & ENTERAL NUTRITION,2018,(01):308.[doi:10.16151/j.1007-810x.2018.05.013]
[2]张 珊,张 伟,李秀华,等.合生素补充联合生活方式干预对非酒精性脂肪肝病人肝硬化和 免疫相关指标的影响[J].肠外与肠内营养杂志,2019,(05):286.[doi:DOI : 10.16151/j.1007-810x.2019.05.007]
　ZHANG Shan,ZHANG Wei,LI Xiu-hua,et al.Effect of synbiotic supplementary combined with lifestyle intervention on liver cirrhosis and immune related indexes in nonalcoholic fatty liver disease[J].PARENTERAL & ENTERAL NUTRITION,2019,(01):286.[doi:DOI : 10.16151/j.1007-810x.2019.05.007]
[3]盛 翔,朱瑞娟,李苏宜.肠道微生态与宫颈癌合并放射性肠损伤的临床研究[J].肠外与肠内营养杂志,2020,(02):78.[doi:10.16151/j.1007-810x.2020.02.004]
　SHENG Xiang,ZHU Rui-juan,LI Su-yi.Clinical study of intestinal microecology and intestinal radiation injury in cervical cancer patients[J].PARENTERAL & ENTERAL NUTRITION,2020,(01):78.[doi:10.16151/j.1007-810x.2020.02.004]
[4]青 青,袁丹凤,谢 玥,等.肝硬化食管胃曲张静脉内镜治疗术后饮食策略 与预后的关系:系统评价[J].肠外与肠内营养杂志,2020,(02):84.[doi:10.16151/j.1007-810x.2020.02.005]
　QING Qing,YUAN Dan-feng,XIE Yue,et al.Dietary strategies and the relationships with prognosis after endoscopic treatments of gastroesophageal varices in patients with cirrhosis: a systematic review[J].PARENTERAL & ENTERAL NUTRITION,2020,(01):84.[doi:10.16151/j.1007-810x.2020.02.005]
[5]张佩彦,秦肖含,王玉珍.肌少症与肝硬化的研究进展[J].肠外与肠内营养杂志,2022,(01):57.[doi:DOI : 10.16151/j.1007-810x.2022.01.011]
　ZHANG Pei-yan,QIN Xiao-han,WANG Yu-zhen.Research progress of sarcopenia in patients with cirrhosis[J].PARENTERAL & ENTERAL NUTRITION,2022,(01):57.[doi:DOI : 10.16151/j.1007-810x.2022.01.011]
[6]马翠翠,宋 洁,娄婷婷,等.有营养风险的肝硬化病人血清瘦素与脂联素变化及其预测营养风险的可行性[J].肠外与肠内营养杂志,2023,(03):148.[doi:10.16151/j.1007-810x.2023.03.005]
　MA Cui-cui,SONG Jie,LOU Ting-ting,et al.Changes of serum leptin and adiponectin in patients with cirrhosis at nutritional risk and the feasibility of predicting nutritional risk[J].PARENTERAL & ENTERAL NUTRITION,2023,(01):148.[doi:10.16151/j.1007-810x.2023.03.005]
[7]刘晏东,邓 强,彭冉东,等.基于肠道微生态探析肌骨衰减疾病的研究概况[J].肠外与肠内营养杂志,2023,(05):309.[doi:10.16151/j.1007-810x.2023.05.010]
　LIU Yan-dong,DENG Qiang,PENG Ran-dong,et al.An overview of research based on intestinal microecology to explore musculoskeletal attenuation diseases[J].PARENTERAL & ENTERAL NUTRITION,2023,(01):309.[doi:10.16151/j.1007-810x.2023.05.010]

备注/Memo

备注/Memo:
基金项目 ：山东省省级临床重点专科建设基金（SLCZDZK-0701）；山东省胆胰肿瘤精品特色专科建设基金（SLCZDZK-2401）通讯作者 ：陈强谱，E-mail：drcqp@263.net
更新日期/Last Update: 1900-01-01